Compare HIMX & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | ARQT |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 3.3B |
| IPO Year | 2006 | 2020 |
| Metric | HIMX | ARQT |
|---|---|---|
| Price | $8.47 | $26.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.83 |
| AVG Volume (30 Days) | 827.1K | ★ 1.8M |
| Earning Date | 02-12-2026 | 02-24-2026 |
| Dividend Yield | ★ 4.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $866,315,000.00 | $317,929,000.00 |
| Revenue This Year | N/A | $85.83 |
| Revenue Next Year | $9.99 | $30.72 |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $5.66 | $11.13 |
| 52 Week High | $13.91 | $31.77 |
| Indicator | HIMX | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 39.57 |
| Support Level | $8.05 | $25.35 |
| Resistance Level | $8.64 | $26.93 |
| Average True Range (ATR) | 0.27 | 1.45 |
| MACD | 0.01 | -0.43 |
| Stochastic Oscillator | 54.67 | 17.04 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.